Neurology and psychiatry therapies: overcoming challenges for strategic market access and competitive advantage
Although neurology and psychiatry indications such as depression, schizophrenia, and migraine are characterized by mature treatment landscapes and established therapies, there is still space for new entrants. These can be differentiated by efficacy in patient subpopulations, an improved side-effect profile, or convenient administration.
Evaluating commercial and market access risks and opportunities
Disease-modifying therapies could be game-changers in neurology and psychiatry indications such as amyotrophic lateral sclerosis, dementia, and Parkinson’s disease. However, you may find it challenging to identify evidence to support market access, pricing, and reimbursement; for example, it is difficult to show patient-relevant outcomes for diseases that progress slowly over many years.
Gaining unique, targeted insights on pricing and reimbursement challenges across major markets
Our expertise in this therapy area provides the insight you need to navigate these challenges. Examples of the indications we have worked in include:
- Alzheimer’s disease
- amyotrophic lateral sclerosis
- multiple sclerosis
- Parkinson’s disease
We can work with you at an early stage in the development of your neurology and psychiatry product to help you establish your pricing, reimbursement, and market access strategy. Alternatively, we can guide you through the whole process with evidence generation, evidence synthesis, and communication. Or you may have a one-off problem; we would like to hear from you so we can look at how we would address it.Request a call